viatris glp-1 receptor agonist medications for Weight Loss: Semaglutide vs Tirzepatide vs Retat – Revolution Health & Wellness How GLP-1 medications are transforming
Description
doi: 10.1016/j.cmet.2021.12.010 Summary Keywords GIP, GLP-1, obesity, weight loss, tirzepatide, GLP-1R agonists, GIP receptor agonists, Citation Zaffina I, Pelle MC, Armentaro G, Giofr F, Cassano V, Sciacqua A and Arturi F (2023) Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity
Retatrutide has the unique dysesthesia concern that affects up to 20% of people at the highest dose
Our pharmacy partner is Olympia Pharmaceuticals in Orlando, FL a 503B FDA-registered, cGMP outsourcing facility with more than 35 years in sterile compounding
The authors suggest this may be because most patients in their study were using GLP-1 RAs to manage diabetes rather than obesity, and because cancer treatments such as chemotherapy, steroids, and endocrine therapy can reduce the drugs weight-loss effects
The highest dose (2.4 mg of each agonist) decreased body weight in participants with overweight by 17% in 20 weeks 90
